

Ex Ship Manager - Print Your Label(s)

P4

From: Origin ID: ZWIA (302) 773-0071  
Doris Duffy  
E. I. du Pont de Nemours & Co.  
1007 Market Street  
D-7096-1  
Wilmington, DE 19898



J18201805258725

SHIP TO: (202) 564-3810 BILL SENDER  
Attn: 8(e) Coordinator  
US Envir Protection Agency ICC Bldg  
DOC PROC CT MAIL CODE 7407M RM 6428  
1201 CONSTITUTION AVENUE, N.W.  
WASHINGTON, DC 20004

Ship Date: 02AUG10  
ActWgt: 1 0 LB  
CAD 4554543/INET3060


Delivery Address Bar Code



Ref #  
Invoice #  
PO #  
Dept #

TRK# 7989 0605 3667  
0201

TUE - 03 AUG A1  
PRIORITY OVERNIGHT



ZD RDVA

20004

DC-US

DCA



588G38E A4 9A24

- Acute Inhalation Toxicity Study

An acute inhalation toxicity study was conducted in accordance to OECD guideline 403. Male and female Wistar rats were exposed by inhalation to the test substance at 5.1 mg/L over a 4-hour period. All animals survived. The animals showed accelerated or shallow respiration during the 4 hour exposure and on the test day. Additionally on the test day nasal discharge, ruffled fur, staggering unsteady gait and deteriorated general state was noted. Ruffled fur continued on day 1 after exposure and on day 2 all animals were free of symptoms.

- Acute Dermal Toxicity Study

In a dermal LD50 study, 5 male and 5 female rats were dosed at 2000 mg/kg of body weight. The test material remained in contact with the skin for 24 hours. After 24 hours, the skin was washed with warm water. Observations for mortality, local reactions, and behavioral abnormalities were continued for a total of 14 days following the skin applications. All animals survived. Clinical signs included dyspnoea, unsettled behavior and poor general state within the first 2 hours of exposure.

- Human Exposure

A U.S. FDA presentation reported that at least three people had died and more than 100 had become ill after taking unregulated new products, which are listed as "party drugs" on internet sites, advertised in muscle-building magazines, and sold in health food stores as dietary supplements to aid in sleep. These products contain the test substance. According to FDA, the test substance can cause dangerously low respiratory rates, unconscious, vomiting, seizures and death. In addition, this substance may also increase the effects of alcohol, and is even more dangerous when consumed with other depressant drugs.

Sincerely,

*A. Michael Kaplan*  
(duel)

A. Michael Kaplan, Ph.D.  
Director - Regulatory Affairs

AMK: clp  
(302) 366-5260



328909  
DuPont Haskell Global Centers  
for Health and Environmental Sciences  
1090 Elkton Road, P.O. Box 50  
Newark, DE 19714-0050

RECEIVED  
JUL 30 11:34

August 02, 2010

Via Federal Express

Document Processing Center (Mail Code 7407M)  
Room 6428  
Attention: 8(e) Coordinator  
Office of Pollution Prevention and Toxics  
U.S. Environmental Protection Agency, ICC Building  
1201 Constitution Ave., NW  
Washington, DC 20004

**Public Copy**  
**No CBI**

8EHQ-0810-17815B



Dear 8(e) Coordinator:

1,4-Butanediol (CAS Number 110-63-4)  
8EHQ-10-17815

DuPont received information from a third party on the above-referenced substance. DuPont has reviewed the information for reportability under TSCA §8(e) and provides below a summary of the information that has been determined to meet EPA's TSCA §8(e) criteria for reporting. It is unknown whether the information reported below has been previously reported to EPA by any third party or is otherwise considered known to the Administrator under TSCA §8(e) guidance.

Test substance: 1,4-Butanediol (CAS Number 110-63-4)

- Acute Oral Toxicity Study

A test group consisting of 5 rats/sex was treated by single gavage dose with an aqueous solution of the test substance. The animals were observed for mortality and for clinical symptoms of toxicity. The rats were weighed prior treatment and thereafter, day 3, day 7 and day 13 post-treatment. At the end of the observation period of 14 days, the surviving animals were sacrificed for the purpose of necropsy; animals that died during the observations period also were subjected to necropsy. Clinical signs observed in male rats included dyspnea, apathy, abnormal position, staggering, atony, unusual pain reflex, unusual cornea reflex, narcotic-like state, tremor, scrubby fur, exsiccosis, exophthalmus, and poor general state. In female rats, clinical sign included dyspnea, apathy, abnormal position, staggering, atony, unusual pain reflex, unusual cornea reflex, narcotic-like state, tremor, spastic gait, scrubby fur, loss of hair, exsiccosis, exophthalmus, and poor general state. The LD50 for female rats was 1670 mg/kg body weight and for male rats was 1350 mg/kg body weight.

DCN:89100000292





ORIGINAL

**TSCA NON-CONFIDENTIAL BUSINESS INFORMATION**

DOCUMENT DESCRIPTION	DOCUMENT CONTROL NUMBER	DATE RECEIVED
8FHQ-10-17815	89100000292	8/3/10

COMMENTS:

**DOES NOT CONTAIN CBI**